Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

Contributed by: ACCESS Newswire

Logo

Tags

Biotechnology

NASDAQ:XBIO

Xenetic Biosciences, Inc.

Company Update

More Like This

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

e-therapeutics Announces Business Updates and Interim Results

PR Newswire associated0

Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals, collaborate on Genetic Medicines Project with support from UKRI Innovate UK and Canadian R&D Funding

GlobeNewswire associated0

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

Merus N.V. Announces Proposed Public Offering of Common Shares

PR Newswire associated0

TriNetX Enhances its Ability to Federate Genomics Data Across its Global Network of Providers through the Acquisition of Key Assets of Zetta Genomics

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model